From scientists to business leaders, there’s one thing most people can agree on – life will not return to normal and our economy will not reach maximum production until a vaccine for COVID-19 is in hand. To find this vaccine, the convergence between tech and medicine is creating a biotechnology revolution.
Operation Warp Speed (OWS), an initiative in the United States, aims to deliver over 300 million doses of a safe, effective vaccine for COVID-19 by January 19, 2021.
And as of this writing, what we call a new, viable “Super Vaccine” is pushing to begin production of up to one billion doses. Right now, a tiny company behind the Super-Vaccine has a mere $60 million a year in sales.
Living in Washington, D.C., it’s good to see that COVID-19 cases, which peaked on April 30, continue to decline. As a result, restaurants, retail stores, and some barbershops have started to open in a limited capacity.
But that reopening isn’t happening everywhere.
There are still thousands of new cases daily across the United States and many states that have started to open back up such as Texas, California, and Florida continue to see a rise in new COVID-19 cases.
When we spoke on Tuesday, I made a bold prediction: the Covid-19 outbreak, while serious, will not be as bad as the worst-case predictions would have it.
For one, much of the country is already on lock-down, cutting off the spread of the disease. That is buying us some valuable time as researchers race to find a cure or at least a good treatment option.
And I’m happy to report there have been some exciting developments in the search for treatments and vaccines against Covid-19
Last week, I noted that most vaccine research remains rooted in 1950s technology.
Despite mapping the entire human genome back in April 2004, drug firms and scientists still rely on slowly growing viruses inside chicken eggs to create a vaccine.
This takes a lot of time – and a lot of eggs.
But the Covid-19 pandemic has them racing to find a treatment using novel and fascinating science.
My wife and I recently helped our daughter Jordan find a reliable used car.
And since Jordan only recently got her grad degree, I have to say she was pretty price sensitive.
She had roughly $9,000 to put down and wanted to limit her payments to about $100 a month, so there wasn’t a lot of wiggle room on cost. She bought, a 2009, one-owner, fully loaded Honda CRV with only 45,000 miles on it.
I’m bringing this up to you because I think our recent experience illustrates a very important point for tech investors.
When it comes to putting your money in stocks that can crush the market, don’t let high “sticker prices” warn you off of great opportunities to build lasting wealth.
Instead, you have to focus on the long-term upside. You know, it’s the old saw by Warren Buffett that price is what you pay but “value is what you get.”
And that really comes into play with a firm that is pioneering the field of robotic surgery.
At first glance, $600 a share seems steep. But this is a stock that could hit $1,800 a shares in as little as seven years.
There’s no doubt about it. We are living in a time of astounding financial opportunities.
Last year, was a great one year for the average retail investor, continuing the epic bull market that began in March 2009. As we move into 2020, it looks like it has the potential to keep right on going.
The terrific economy that we’ve had has helped propel stocks to record highs. Unemployment remains at 50-year lows as real income adjusted for inflation is moving up for millions of Americans.
In a case like this, you’d think all you have to do from here on out is just coast on autopilot. After all, the bellwether S&P 500 was up roughly 28.9% for the year as of the close on December 31.
But, as impressive as that sounds, you could do much better in 2020.
That’s because the S&P 500’s numbers for the year are nothing compared to the gains members of my monthly tech investing newsletter, the Nova-X Report, scored in 2019.
Indeed, our three best performers for the year more than doubled the S&P.